revenu increas net profit declin yoy
net profit miss market full year forecast month
organ revenu growth yoy net profit exclud one-
off declin
net profit drag surg cost lower associ
incom sell market expens per sale increas
 expens increas yoy
manag guid expens stay level due
product enter late stage clinic trial expect rituximab
biosimilar approv
cut net profit forecast
factor higher expens thu cut tp
maintain outperform new tp base
healthcar servic medic devic maintain
outperform expect rituximab biosimilar approv
near term deriv a-shar target price
use method arriv neutral
revenu net profit compani announc result revenu
increas net profit declin yoy net profit
miss market full year forecast nine-month revenu
increas yoy revenu growth exclud chang
financi report compli two-invoic polici yoy
net profit exclud one-off nine-month declin yoy
net profit drag surg cost lower associ
margin cost gross margin declin slightli gland
pharma overal
lower gross margin compar fosun
busi sell cost revenu increas pp due
compli two-invoic polici penetr drug sale admin
expens sale increas pp due amortis
 last year cost surg reach
total sale invest incom declin nine-month due
higher loss joint ventur
estimate pot chg tp
number share mn
chg prev ep
 servic growth med-tech segment growth
davinci robot sale declin due strict hospit facil
quota system manag guid pharmaceut organ
sale stronger
 pipelin
manag guid expens stay level
next
year due pipelin product enter late stage clinic
trial howev impact net profit margin dilut
revenu grow rituximab biosimilar api activ pharmaceut
ingredi finish drug pass site inspect
china center drug evalu compani expect
approv
cut tp maintain outperform
cut net profit forecast
factor higher expect expens hand
cut price-to-earnings multipl segment use drive sotp
valuat new tp base sotp model assum
medic devic maintain outperform compani
compani trade price-to-earnings use method
drive share target price cut tp
approv near
pharma segment deliv growth yoy exclud
tp
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
serena shao katherin fu certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
price rate histori shanghai fosun pharmaceut group co ltd
signifi initi assumpt coverag
price rate histori shanghai fosun pharmaceut group co ltd
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european rate base stock total return rel analyst coverag univers consist
compani cover analyst within relev sector outperform repres attract neutral less attract
underperform least attract invest opportun latin american asia stock exclud japan australia rate
base stock total return rel averag total return relev countri region benchmark india bse sensex index
prior octob canadian rate base stock absolut total return potenti current share price
rel attract stock total return potenti within analyst coverag univers australian new zealand stock
expect total return calcul includ roll dividend yield outperform rate assign greater
equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may
rang outperform under-perform rate overlap neutral threshold oper
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
charl martineau pm univers toronto rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
